A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

(2016) Cora Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

(2015) Anders Olsson et al.   Journal for ImmunoTherapy of Cancer

Maintenance therapy in ovarian cancer

(2014) Saira Khalique et al.   CURRENT OPINION IN ONCOLOGY

Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

(2014) L. Shen et al.   Cancer Immunology Research

Mechanisms of action of tasquinimod on the tumour microenvironment

(2013) E. Raymond et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

S100A9 Interaction with TLR4 Promotes Tumor Growth

(2012) Eva Källberg et al.   PLoS One

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

(2011) Roberto Pili et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER